Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) EPS (Weighted Average and Diluted) (2018 - 2025)

Ironwood Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 11 years, with the latest figure at $0.01 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) changed 0.0% year-over-year to $0.01; the TTM value through Dec 2025 reached $0.15, up 1600.0%, while the annual FY2025 figure was $0.15, 1400.0% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.01 at Ironwood Pharmaceuticals, down from $0.23 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $2.39 in Q2 2021 and bottomed at -$6.84 in Q2 2023.
  • The 5-year median for EPS (Weighted Average and Diluted) is $0.21 (2022), against an average of -$0.11.
  • The largest annual shift saw EPS (Weighted Average and Diluted) crashed 3357.14% in 2023 before it surged 1500.0% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.24 in 2021, then rose by 12.5% to $0.27 in 2022, then crashed by 66.67% to $0.09 in 2023, then tumbled by 88.89% to $0.01 in 2024, then fell by 0.0% to $0.01 in 2025.
  • Per Business Quant, the three most recent readings for IRWD's EPS (Weighted Average and Diluted) are $0.01 (Q4 2025), $0.23 (Q3 2025), and $0.14 (Q2 2025).